PMID- 15899610
OWN - NLM
STAT- MEDLINE
DCOM- 20050608
LR  - 20151119
IS  - 1769-6917 (Electronic)
IS  - 0007-4551 (Linking)
VI  - 91 Suppl 4
DP  - 2004 Dec 1
TI  - [Assessment of HER2 status in breast cancer].
PG  - S211-5
AB  - HER2-positive status is the sole criterion for identifying patients with breast 
      cancer for Herceptin (trastuzumab) therapy. Accurate assessment of HER2 status is 
      essential to ensure that all patients who may benefit from Herceptin are 
      correctly identified. There are several assays available to determine HER2 
      status: the most common in routine clinical practice are immunohistochemistry 
      (IHC) and fluorescence in situ hybridization (FISH). The pros and cons of those 
      two tests and the other upcoming methods for assessing HER2 status (with a focus 
      on chromogenic in situ hybridization CISH recently approved by European 
      Commission) are described in this manuscript. The importance of adhesion to 
      quality assurance programs is underlined. Finally, the different national testing 
      guidelines are discussed.
FAU - Penault-Llorca, Frederique
AU  - Penault-Llorca F
AD  - Departement de pathologie, Centre Jean-Perrin, 58, rue Montalembert, BP 392, 
      63011 Clermont-Ferrand. fpenault@cjp.fr
FAU - Cayre, Anne
AU  - Cayre A
LA  - fre
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Actualite des tests HER2 dans le cancer du sein.
PL  - France
TA  - Bull Cancer
JT  - Bulletin du cancer
JID - 0072416
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Antineoplastic Agents)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
RN  - P188ANX8CK (Trastuzumab)
SB  - IM
MH  - Antibodies, Monoclonal/therapeutic use
MH  - Antibodies, Monoclonal, Humanized
MH  - Antineoplastic Agents/therapeutic use
MH  - Breast Neoplasms/*chemistry/drug therapy
MH  - Female
MH  - Genes, erbB-2
MH  - Humans
MH  - Immunohistochemistry/*methods
MH  - In Situ Hybridization, Fluorescence/*methods
MH  - Receptor, ErbB-2/*analysis/immunology
MH  - Trastuzumab
RF  - 34
EDAT- 2005/05/19 09:00
MHDA- 2005/06/09 09:00
CRDT- 2005/05/19 09:00
PHST- 2005/05/19 09:00 [pubmed]
PHST- 2005/06/09 09:00 [medline]
PHST- 2005/05/19 09:00 [entrez]
PST - ppublish
SO  - Bull Cancer. 2004 Dec 1;91 Suppl 4:S211-5.